| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Chardan Capital analyst Geulah Livshits maintains Achilles Therapeutics (NASDAQ:ACHL) with a Buy and lowers the price target...
Piper Sandler analyst Joseph Catanzaro downgrades Achilles Therapeutics (NASDAQ:ACHL) from Overweight to Neutral and lowers ...
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow...
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong prelimi...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow ...
Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate ...
Improved VELOS manufacturing process delivering higher cNeT doses. Protocols updated to evaluate the benefit of enhanced hos...
